Plasminogen Activator Inhibitor-1 as a Potential Marker for the Malignancy of Esophageal Squamous Cell Carcinoma

Clinical Cancer Research

Volumn 10, Issue 4, 2004, Pages 1375-1378

  Sakakibara, Takumi ^a   Hibi, Kenji ^a   Kodera, Yasuhiro ^a   Ito, Katsuki ^a   Akiyama, Seiji ^a   Nakao, Akimasa ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; ESOPHAGUS CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SQUAMOUS CELL CARCINOMA;

AGED; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 1642312903     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0196     Document Type: Article

References (26)

1. Jiang, W., Zhang, Y. J., Kahn, S. M., Hollstein, M. C., Santella, R. M., Lu, S. H., Harris, C. C., Montesano, R., and Weinstein, I. B. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc. Natl. Acad. Sci. USA, 90: 9026-9030, 1993.
2. Tsuda, T., Tahara, E., Kajiyama, G., Sakamoto, H., Terada, M., and Sugimura, T. High incidence of coamplification of hst1 and int2 genes in human esophageal carcinomas. Cancer Res., 49: 5505-5508, 1989.
3. Hollstein, M. C., Metcalf, R. A., Welsh, J. A., Montesano, R., and Harris, C. Frequent mutation of the p53 gene in human esophageal cancer. Proc. Natl. Acad. Sci. USA, 87: 9958-9961, 1990.
4. Zhou, X., Tarmin, L., Yin, J., Jiang, H. Y., Suzuki, H., Rhyu, M. G., Abraham, J. M., and Meltzer, S. J. The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene, 9: 3737-3741, 1994.
5. Potempa, J., Korzus, E., and Travis, J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J. Biol. Chem., 269: 15957-15960, 1994.
6. Nekarda, H., Schmitt, M., Ulm, K., Wenninger, A., Vogelsang, H., Becker, K., Roder, J. D., Fink, U., and Siewert, J. R. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res., 54: 2900-2907, 1994.
7. Berger, D. H. Plasmin/plasminogen system in colorectal cancer. World J. Surg., 26: 767-771, 2002.
8. Foekens, J. A., Peters, H. A., Look, M. P., Portengen, H., Schmitt, M., Kramer, M. D., Brunner, N., Janicke, F., Meijer-van Gelder, M. E., Henzen-Logmans, S. C., van Putten, W. L., and Klijn, J. G. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res., 60: 636-643, 2000.
9. Chambers, S. K., Ivins, C. M., and Carcangiu, M. L. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int. J. Cancer, 79: 449-454, 1998.
10. Konecny, G., Untch, M., Pihan, A., Kimmig, R., Gropp, M., Stieber, P., Hepp, H., Slamon, D., and Pegram, M. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin. Cancer Res., 7: 1743-1749, 2001.
11. Cantero, D., Friess, H., Deflorin, J., Zimmermann, A., Brundler, M. A., Riesle, E., Korc, M., and Buchler, M. W. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br. J. Cancer, 75: 388-395, 1997.
12. Hibi, K., Nakamura, H., Hirai, A., Fujikake, Y., Kasai, Y., Akiyama, S., Ito, K., and Takagi, H. Loss of H19 imprinting in esophageal cancer. Cancer Res., 56: 480-482, 1996.
13. Hibi, K., Takahashi, T., Sekido, Y., Ueda, R., Hida, T., Ariyoshi, Y., and Takagi, H. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene, 6: 2291-2296, 1991.
14. Castello, R., Estelles, A., Vazquez, C., Falco, C., Espana, F., Almenar, S. M., Fuster, C., and Aznar, J. Quatitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type-1, and tissue metalloproteinase inhibitor type-1 gene expressions in primary breast cancer. Clin. Chem., 48: 1288-1295, 2002.
15. Pasco, J. A., Henry, M. J., Kotowicz, M. A., Collier, G. R., Ball, M. J., Ugoni, A. M., and Nicholson, G. C. Serum leptin levels are associated with bone mass in nonobese women. J. Clin. Endocrinol. Metab., 86: 1884-1887, 2001.
16. Wang, E. J., Kripke, D. F., Stein, M. T., and Parry, B. L. Measurement of illumination exposure in postpartum women. BMC Psychiatry, 3: 5, 2003.
17. Pedersen, H., Brunner, N., Francis, D., Osterlind, K., Ronne, E., Hansen, H. H., Dano, K., and Grondahl-Hansen, J. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res., 54: 4671-4675, 1994.
18. Umeda, T., Eguchi, Y., Okino, K., Kodama, M., and Hattori, T. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. J. Pathol., 183: 388-397, 1997.
19. Duffy, M. J., Maguire, T. M., McDermott, E. W., and O'Higgins, N. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J. Surg. Oncol., 71: 130-135, 1999.
20. Hofmann, R., Lehmer, A., Buresch, M., Hartung, R., and Ulm, K. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer (Phila.), 78: 487-492, 1996.
21. Knoop, A., Andreasen, P. A., Andersen, J. A., Hansen, S., Laenkholm, A. V., Simonsen, A. C., Andersen, J., Overgaard, J., and Rose, C. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br. J. Cancer, 77: 932-940, 1998.
22. Grondahl-Hansen, J., Christensen, I. J., Rosenquist, C., Brunner, N., Mouridsen, H. T., Dano, K., and Blichert-Toft, M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res., 53: 2513-2521, 1993.
23. Cho, J. Y., Chung, H. C., Noh, S. H., Roh, J. K., Min, J. S., and Kim, B. S. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer (Phila.), 79: 878-883, 1997.
24. Ferrara, N., Chen, H., Davis-Smyth, T., Gerber, H. P., Nguyen, T. N., Peers, D., Chisholm, V., Hillan, K. J., and Schwall, R. H. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med., 4: 336-340, 1998.
25. Folkman, J., Browder, T., and Palmblad, J. Angiogenesis research: guidelines for translation to clinical application. Thromb. Haemostasis, 86: 23-33, 2001.
26. Bajou, K., Noel, A., Gerard, R. D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N. E., Carmeliet, P., Collen, D., and Foidart, J. M. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med., 4: 923-928, 1998.